CpG methylation of MGMT and hMLH1 promoter in hepatocellular carcinoma associated with hepatitis viral infection.
about
Promoter methylation of MLH1, PMS2, MSH2 and p16 is a phenomenon of advanced-stage HCCsTumor suppressor and hepatocellular carcinomaSilencing of MGMT expression by promoter hypermethylation in the metaplasia-dysplasia-carcinoma sequence of Barrett's esophagusPhase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinomaInvolvement of DNA damage response pathways in hepatocellular carcinoma.O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction.Epigenetic mechanisms involved in the pathogenesis of hepatobiliary malignanciesSilencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer.Methylation of multiple genes in hepatitis C virus associated hepatocellular carcinomaRapid identification of promoter hypermethylation in hepatocellular carcinoma by pyrosequencing of etiologically homogeneous sample poolsAberrant methylations in cancer cells: where do they come from?Role of human ribosomal RNA (rRNA) promoter methylation and of methyl-CpG-binding protein MBD2 in the suppression of rRNA gene expressionImmunoepigenetics: the unseen side of cancer immunoediting.Quantitative methylation analysis reveals distinct association between PAX6 methylation and clinical characteristics with different viral infections in hepatocellular carcinomaDNA methylation in hepatocellular carcinoma.Molecular alterations in the carcinogenesis and progression of hepatocellular carcinoma: Tumor factors and background liver factors.Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft modelBRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease.
P2860
Q28305454-9F0E6BA2-BE3B-4975-8080-F67D8920DD5DQ28389231-CC21B4DE-2B67-4130-918D-21A8B54910DBQ30412980-30BF7706-B72C-48BC-B6E1-5EB2E2DC2F50Q33426556-75994508-B676-4968-97BC-F6412AA949AAQ33616812-7BD86F5E-2157-43BF-B881-664C88DAA15AQ33804528-DCA82D5B-45DF-4A5B-A978-9F7B848405D7Q33907989-0E46C781-425C-4FB4-93FC-EA5B93A28C6DQ34280188-0C2C4841-A917-4210-B149-5EDEBCECA9B3Q34462989-CC42424B-9712-4542-A721-4866DE514A64Q35988103-5D143B0B-5416-4EB5-8C3A-4B929037AE7DQ36093347-8049BD53-3A43-4D30-8D42-BAD7E2870D2CQ36459023-FAF30C61-F269-4D3A-8F02-047D4C3F2FF1Q36666346-3DBD9B4D-4EDD-4A68-BB51-D413A1380DC3Q36825828-135C6D83-F304-4D38-91F2-09C846226595Q37113559-5194C500-F63D-4A83-B190-BF77D7A0E51DQ37407115-34BED988-8F71-4564-A76D-2C9DBB7A152BQ37467299-ECC2BD5C-BEA9-4592-93F4-FCC2E545F5DFQ41925341-3AB541BC-2540-4074-9D39-8203A5732629
P2860
CpG methylation of MGMT and hMLH1 promoter in hepatocellular carcinoma associated with hepatitis viral infection.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
CpG methylation of MGMT and hM ...... ith hepatitis viral infection.
@ast
CpG methylation of MGMT and hM ...... ith hepatitis viral infection.
@en
type
label
CpG methylation of MGMT and hM ...... ith hepatitis viral infection.
@ast
CpG methylation of MGMT and hM ...... ith hepatitis viral infection.
@en
prefLabel
CpG methylation of MGMT and hM ...... ith hepatitis viral infection.
@ast
CpG methylation of MGMT and hM ...... ith hepatitis viral infection.
@en
P2093
P2860
P356
P1476
CpG methylation of MGMT and hM ...... with hepatitis viral infection
@en
P2093
H Yakushiji
K Miyazaki
M Fukuhara
M Sekiguchi
S Matsukura
T Nakagawachi
P2860
P2888
P304
P356
10.1038/SJ.BJC.6600743
P407
P577
2003-02-01T00:00:00Z